Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
    Finance

    Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers

    Published by Global Banking & Finance Review®

    Posted on November 21, 2025

    2 min read

    Last updated: January 20, 2026

    Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationpartnershiphealthcareinsurancetechnology

    Quick Summary

    Waltz Health partners with Novo Nordisk and Eli Lilly to sell weight-loss drugs directly to employers, aiming to streamline access and pricing.

    Novo, Lilly Team Up with Waltz to Offer Weight-Loss Drugs to Employers

    (Reuters) -Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, bypassing traditional drug sales channels.

    Waltz said employees can access the drugs through their existing healthcare providers or a telehealth option integrated into the program, which is expected to launch on January 1 next year.

    The direct-to-employer structure is designed to eliminate "unnecessary friction and delivers consistent pricing, adherence monitoring and real-time clinical review," the company added.

    Danish drugmaker Novo and its U.S. rival Lilly have been trying to eliminate unapproved, compounded versions, made by combining, mixing or altering drug ingredients, of their blockbuster weight-loss treatments.

    The drugmakers currently dominate the lucrative obesity treatment market, which analysts estimate could be worth $150 billion annually by the early 2030s, with their highly effective drugs designed to mimic the appetite-suppressing GLP-1 hormone.

    "Transparent initiatives like these enable more employers to opt in to coverage for authentic, FDA-approved GLP-1 medicines while providing people who need care with a seamless experience that allows them to prioritize their health," a Novo Nordisk spokesperson told Reuters.

    (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)

    Key Takeaways

    • •Waltz Health launches program for direct drug sales to employers.
    • •Novo Nordisk and Eli Lilly collaborate with Waltz Health.
    • •Program bypasses traditional drug sales channels.
    • •Focus on FDA-approved GLP-1 weight-loss drugs.
    • •Program aims to eliminate compounded drug versions.

    Frequently Asked Questions about Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers

    1What is a weight-loss drug?

    Weight-loss drugs are medications designed to help individuals lose weight by suppressing appetite, increasing feelings of fullness, or reducing fat absorption. They are often prescribed for obesity management.

    2What is the GLP-1 hormone?

    GLP-1 (glucagon-like peptide-1) is a hormone that plays a role in regulating appetite and blood sugar levels. It is often targeted by weight-loss medications to help control hunger and promote weight loss.

    More from Finance

    Explore more articles in the Finance category

    Image for Hungary's opposition Tisza promises wealth tax, euro adoption in election programme
    Hungary's opposition Tisza promises wealth tax, euro adoption in election programme
    Image for Farmers report 'catastrophic' damage to crops as Storm Marta hits Spain and Portugal
    Farmers report 'catastrophic' damage to crops as Storm Marta hits Spain and Portugal
    Image for If US attacks, Iran says it will strike US bases in the region
    If US attacks, Iran says it will strike US bases in the region
    Image for Olympics-Biathlon-Winter Games bring tourism boost to biathlon hotbed of northern Italy
    Olympics-Biathlon-Winter Games bring tourism boost to biathlon hotbed of northern Italy
    Image for Analysis-Bitcoin loses Trump-era gains as crypto market volatility signals uncertainty
    Analysis-Bitcoin loses Trump-era gains as crypto market volatility signals uncertainty
    Image for NatWest closes in on $3.4 billion takeover of wealth manager Evelyn, Sky News reports
    NatWest closes in on $3.4 billion takeover of wealth manager Evelyn, Sky News reports
    Image for Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
    Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
    Image for US pushes Russia and Ukraine to end war by summer, Zelenskiy says
    US pushes Russia and Ukraine to end war by summer, Zelenskiy says
    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    View All Finance Posts
    Previous Finance PostADNOC's Covestro takeover gets final regulatory approval in Germany
    Next Finance PostExclusive-Kering CEO plans 'House of Dreams' investment arm to help trim reliance on Gucci